In a report with 12 European patients, neoplastic cells appeared to consistently express CD2 with CD16 and the presence of CD16 in ANKL patients could distinguish the disease from ENKTL, which was usually CD16 negative (12). The gene discussed is CD2; the disease is aggressive NK-cell leukemia.